Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085632 (apathy)
 4,089 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This review focuses on the features of pseudotumor cerebri in the pediatric age group. There is no sex predilection in children, and obesity does not appear to be an important factor. Infants and young children may present with irritability, apathy, or somnolence, rather than headache. Dizziness and ataxia may also occur. Papilledema is infrequently noted in pediatric patients if the fontanelles are open or the sutures are split. Pre-adolescents appear more likely than adults or adolescents to have manifestations of their pseudotumor cerebri other than headache and papilledema, including lateral rectus pareses, vertical strabismus, facial paresis, back and neck pain. Among the etiologies that are particularly pertinent to children are tetracycline therapy, malnutrition or renutrition, and the correction of hypothyroidism. Children with pseudotumor cerebri are at risk for visual loss and their visual function must be closely monitored. Surgical intervention is imperative when vision is threatened.
 ...
PMID:Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). 147 50

A clinical and immunological study is presented of 1030 practically healthy persons inhabiting Kiev from the moment of the Chernobyl accident. It was established clinically that during the last 5 years more frequent became acute respiratory viral infections, exacerbation of existing infection foci, appearance of complaints of reduced working capacity, somnolence apathy, increased fatiguability, worsening of memory, periodic subfebrility and oth. This symptom complex was determined as the "increased fatiguability syndrome". It was characterized immunologically by different changes showing most frequently a reduction of the functional activity of natural killers. The authors analyze different variants of immunological disorders in this group of subjects and give practical recommendations on using immunotropic drugs. They emphasize the importance of a service of clinical immunology in Ukraine able to organize special services to the population.
 ...
PMID:[Immunity disorders and the increased fatigability syndrome in the residents of the city of Kiev]. 180 23

PK 11195 is a selective ligand for the peripheral-type benzodiazepine binding sites which exhibits anti-conflict activity in animals. In a pilot open study, PK 11195 was administered to 10 psychiatric inpatients characterized by a rating of at least "moderate" for the item "felt loss of vitality" and a rating of at least "moderate" for the items "anxiety" and/or "inhibition of drive" from the psychopathological scale of the system developed by the Association for Methodology and Documentation in Psychiatry (AMDP). The duration of the study was two weeks, with an initial daily dose of 200 mg of PK 11195 which could be increased up to 400 mg. Patients were assessed weekly using the psychopathological and somatic AMDP scales and at days 0, 4, 7, and 14 using the Hamilton anxiety scale and a checklist of symptoms and side-effects. The results showed significant improvement in the AMDP factor scores related to somatic complaints, depression, anxiety, apathy-retardation, and psycho-organic symptoms. However, anxiolytic activity, confirmed on the Hamilton anxiety scale, remained moderate and reached maximum effect after one week. No side-effects, drowsiness in particular, were reported. This study therefore suggests a potential beneficial activity of PK 11195 on anxiety and inhibition, which merits further investigation in controlled studies.
 ...
PMID:Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. 184 86

Twenty children aged 2 months to 18 years were included in a dose-response study of vigabatrin as add-on therapy to preexisting antiepileptic drugs (up to two per patient). All children had severe refractory epilepsy: partial seizures with or without secondary generalization in 19, and myoclonic seizures in one. After a 2-month observation period and a 1-month add-on placebo period, a fixed dose of add-on vigabatrin was given for 2 months: 1, 1.5, or 2 g/day, according to body weight (mean dose, 60 mg/kg/day). Three patients (15%) became seizure free, and nine (45%) showed a 50% to 99% reduction in seizure frequency. In the 17 patients whose seizures were not totally suppressed, vigabatrin dose was increased for a further 2 months, and in 7 patients who still showed less than 50% reduction in seizure frequency, vigabatrin dose was increased again. Efficacy appeared unchanged by these higher doses. During a 9-month follow-up phase, no tolerance to the effects of vigabatrin was observed, with three children seizure free and 13 (65%) reporting a 50% to 99% reduction in seizure frequency. During the study, adverse effects were recorded in three children (15%), namely drowsiness, constipation, fatigue, and apathy. These effects were generally transient, being observed during the dose-modification phase and disappearing either spontaneously or on reduction of vigabatrin dose. Clinical and laboratory tolerability to vigabatrin appeared to be very good, with no patients having withdrawn from the study because of side effects. A slight reduction in red blood cell count and hemoglobin levels was noted but was of doubtful clinical significance.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Dose-response study of vigabatrin in children with refractory epilepsy. 194 Jan 24

Myxedema results from hypofunction of the thyroid gland. Symptoms include dry skin, loss of and dryness of hair, mental apathy, drowsiness, and sensitivity to cold. Ocular complications associated with myxedema may be the symptoms that first prompt patients to seek a physician or cosmetic surgeon, however, though other symptoms may be present before eyelid myxedema occurs. The case reported here illustrates the value of a correct diagnosis and appropriate medical treatment, and demonstrates how surgical intervention to correct remaining eyelid problems can succeed when it is part of a comprehensive treatment plan.
 ...
PMID:The rare presentation to the cosmetic and plastic surgeon of a patient with myxedema. 207 81

The symptoms of hypothyroidism are protean and include apathy, somnolence, lethargy, personality change, and intellectual deterioration. Many of these symptoms may be related to hypothyroid-induced sleep disorders. Hypothyroidism is associated with abnormal ventilatory drive, abnormal sleep architecture, and sleep apnea. Central, obstructive, and mixed patterns of sleep apnea are commonly observed in hypothyroidism. A case of severe sleep apnea in a grossly myxedematous patient who improved dramatically following thyroid replacement alone is presented. Myxedema is a reversible cause of sleep apnea, and thyroid function testing should be considered in its diagnostic work-up.
 ...
PMID:Sleep apnea, sleep disorders, and hypothyroidism. 276 18

In order to examine the predictive value of risk factors for the Sudden Infant Death Syndrome (SIDS), we have interviewed the parents of 80 SIDS victims and 80 parents of a healthy control group. From these interviews a list of 24 clinical and behavioural symptoms was assembled which appeared to be associated with the risk for SIDS. Out of this list of 24 symptoms the average number of symptoms reported to be observable in SIDS victims was twice as large as the average number of symptoms reported for healthy controls. The following symptoms appeared markedly more often in SIDS victims than in the controls: difficulties in awakening the baby, shrill crying, apathy, few movements during sleep, and cyanosis. We have attempted to consider a possible bias in the report of the parents of deceased infants by the introduction of an "exaggeration factor". By application of Bayes' theorem the highest predictive probability, 2.7%, was found for difficulties in awakening the baby. This is approximately nine times the assumed a priori probability of SIDS of 0.3%. We conclude that behavioural risk factors have a low but still remarkable predictive probability. A behavioural pattern of apathy and sleepiness indicates risk with a high probability.
 ...
PMID:The predictive value of behavioural risk factors for sudden infant death. 322 74

Personal anecdotes suggest that ascent to high altitude can cause mood changes such as depression, apathy, and drowsiness. Observed behaviors at high altitude indicate that people can become more euphoric, irritable, or argumentative. Since there are few systematic and quantitative studies assessing the effects of altitude on mood, this study compared moods measured at two different altitudes and times of day (morning-evening) using a standardized scale. Self-rated moods were determined twice daily in 19 males and 16 females with the Clyde Mood Scale. Baseline values were determined at 200 m; moods were then assessed at 4300 m with one group and at 1600 m with a second group. Friendliness, clear thinking, dizziness, sleepiness, and unhappiness were affected at 4300 m but only sleepiness changed at 1600 m. At 4300 m, the altered moods differed from baseline on the day of arrival (1-4 hours), differed even more after one day (18-28 hours), and returned to baseline by day 2 (42-52 hours). Morning and evening values were similar at each altitude. Therefore, changes in mood states at altitude have a distinct and measurable time course.
 ...
PMID:Mood states at 1600 and 4300 meters terrestrial altitude. 339 Jan 10

Clopenthixol decanoate was given to 20 chronic schizophrenic patients for 11 months in doses ranging from 100 mg initially up to 1000 mg 3-weekly subsequently, according to clinical response and the occurrence of adverse effects. A further 3 patients received the depot injections for periods of 6 to 9 months. Improvement in individual symptoms was rated on a 4-point scale. Unwanted effects were recorded on a checklist and routine biochemical and haematological tests were carried out at the beginning and end of the treatment period. There were highly significant improvements in the mean overall symptom score and in the 5 single symptom scores (hallucinations, delusions, depression, aggressive behaviour and non-aggressive behaviour disturbance). The 2 'negative' symptoms of apathy and social withdrawal showed improvement up to 16 weeks but not at 11 months. The incidence of depression was less at the end of the study than at the time fo entry. Three patients stopped the drug after the sixth month because of extrapyramidal symptoms (2) or drowsiness (1). Three others developed severe extra-pyramidal side-effects. Unwanted effects, though recorded in 70% of patients--drowsiness and extrapyramidal symptoms were the commonest--were for the most part trivial, and were fewer and less severe than they were on entry to the study. There was no evidence of toxicity. It was considered that on the basis of this experience the drug was an effective, safe antipsychotic agent, warranting more extensive clinical trial.
 ...
PMID:Clopenthixol decanoate in schizophrenia. 611 16

ACTH therapy induces transient behaviour disturbances (irritability, restlessness or drowsiness and apathy), parallel to the EEG. changes. These behaviour abnormalities have a positive relationship with cortisolemic levels and clinical results. A clear relationship between ACTH therapy and pseudoatrophic CT findings can be observed.
 ...
PMID:[Collateral transient behavioural changes during ACTH therapy in infantile generalized epilepsy (author's transl)]. 628 84


1 2 3 4 5 6 7 8 Next >>